A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma

  1. Papadopoulos, K.P.
  2. Lopez-Jimenez, J.
  3. Smith, S.E.
  4. Steinberg, J.
  5. Keating, A.
  6. Sasse, C.
  7. Jie, F.
  8. Thyss, A.
Revue:
Leukemia and Lymphoma

ISSN: 1029-2403,  1042-8194

Année de publication: 2016

Volumen: 57

Número: 8

Pages: 1848-1855

Type: Article

DOI: 10.3109/10428194.2015.1113275 GOOGLE SCHOLAR
La source de données: Scopus